Spanish consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria

Fecha de publicación:

Autores de IIS La Fe

  • Eva María Colado Perez

    Autor

  • Isidro Jarque Ramos

    Autor

  • Ramiro Jose Nuñez Vazquez

    Autor

  • Victor Vicente Vilas

    Autor

Participantes ajenos a IIS La Fe

  • Villegas A
  • Arrizabalaga B
  • Gaya A
  • González A
  • Ojeda E
  • Orfao A
  • Ribera JM
  • Urbano-Ispizua Á
  • Grupo de Trabajo de HPN de la Sociedad Española de Hematología y Hemoterapia

Grupos

Abstract

Paroxysmal nocturnal haemoglobinuria (PNH) is an acquired clonal disorder of the haematopoietic progenitor cells due to a somatic mutation in theX-linked phosphatidylinositol glycan class A gene. The disease is characterized by intravascular haemolytic anaemia, propensity to thromboembolic events and bone marrow failure. Other direct complications of haemolysis include dysphagia, erectile dysfunction, abdominal pain, asthenia and chronic renal failure (65% of patients). The disease appears more often in the third decade of life and there is no sex or age preference. Detection of markers associated with glucosyl phosphatidyl inositol deficit by flow cytometry is currently used in the diagnosis of PNH. For years, transfusions have been the mainstay of therapy for PNH. A breakthrough in treatment has been the approval of the humanized monoclonal antibody eculizumab, which works by blocking the C5 complement protein, preventing its activation and therefore haemolysis. Several studies have confirmed that treatment with eculizumab avoids or decreases the need for transfusions, decreases the probability of thrombosis, improves the associated symptomatology and the quality of life in patients with PNH, showing an increase in survival. Because of rapid advances in the knowledge of the disease and its treatment, it may become necessary to adapt and standardize clinical guidelines for the management of patients with PNH.

Datos de la publicación

ISSN/ISSNe:
0025-7753, 1578-8989

MEDICINA CLINICA  ELSEVIER DOYMA SL

Tipo:
Editorial Material
Páginas:
278-278
PubMed:
26895645
Factor de Impacto:
0,223 SCImago
Cuartil:
Q3 SCImago

Citas Recibidas en Web of Science: 10

Documentos

  • No hay documentos

Métricas

Filiaciones mostrar / ocultar

Keywords

  • Celulas progenitoras hematopoyeticas; Hematopoietic progenitor cells; Hemoglobinuria paroxistica nocturna; Mutacion; Mutation; Paroxysmal nocturnal haemoglobinuria

Campos de Estudio

Compartir